ClinicalTrials.gg
CompletedNCT01431963Updated Oct 20, 2016Results posted

Clinical Study of Lamotrigine to Treat Newly Diagnosed Epilepsy

A Phase 3 interventional study of Lamictal in Epilepsy, sponsored by GlaxoSmithKline. Completed at 13 sites in 2 countries. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2016-10-20.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
70
Allocation
Non-randomized
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 36 studies testing lamotrigine in Epilepsy — 2 open to participants now, 2 under way, none of them phase 3. Lamotrigine · Epilepsy.

Enrollment
20th of 36
70 · median 76
Started
2011
with 2 others
Phase 3
12 of 36
none open now
Registered
24th of 36
by date
Lead sponsor
19 of 36
GlaxoSmithKline

Among the 36 studies testing lamotrigine in Epilepsy, this one is the 20th largest by enrollment, is one of 3 that started in 2011, is one of 12 in phase 3, and was the 24th registered.

Epilepsy

1,848 studies on the registry are indexed under Epilepsy; 419 are open to participants now.

Browse Epilepsy studies →

Open to participants now

2 of the 36 studies testing lamotrigine in Epilepsy are open now. Recruiting first, the newest first:

All 2 open studies →

About lamotrigine

Lamotrigine: first FDA approval 1994 (LAMICTAL). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 282 Epilepsy studies recruiting now, 112 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 139 take children under 18; 55 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing lamotrigine in Epilepsy, or all of them as a file.
02

Study summary

This is a multi-center, uncontrolled, open-label study conducted in Japan and South Korea to evaluate the efficacy and safety of lamotrigine monotherapy in subjects with newly diagnosed epilepsy and those with recurrent epilepsy (currently untreated).

The study is composed of baseline, escalation phase, maintenance phase, taper phase and post study examination. During the escalation phase, the investigational product is administered orally at 25 mg/day for 2 weeks, then 50 mg/day for 2 weeks and finally 100 mg/day for 2 weeks. During the maintenance phase, 200 mg/day is administered orally for 24 weeks. However, the dose can be decreased to 100 mg/day if there are safety concerns. Also, if it is confirmed that the seizures cannot be controlled at the dose of 200 mg/day, the dose can be gradually increased up to 400 mg/day by 50-100 mg/day at intervals of at least 1 week. As a rule, lamotrigine should be administered once daily (in the evening), but the dose exceeding 200 mg/day can be administered in two divided doses (in the morning and evening). After the completion of maintenance phase, Japanese subjects who have responded to lamotrigine without tolerability issues are eligible to enter an extension phase of the study if indicated, until either approval of this indication (monotherapy in epilepsy) or after 24 months after LSLV (Last Subject's Last Visit) of the maintenance phase, whichever is sooner.

03

Conditions studied

  • Epilepsy

Browse trials for

04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Target disease: Subjects with newly diagnosed epilepsy or recurrent epilepsy which is untreated, having the following seizure types as classified by the International Classification of Seizures.

    • Partial seizures (with or without secondarily generalisation)
    • Generalized tonic-clonic seizures without focal onset, with or without myoclonus but without other generalized seizure type(s).
  2. Subjects have a confident diagnosis of epilepsy uncomplicated by pseudoseizures (psychogenic nonepileptic seizures).
  3. Subjects have had at least 2 seizures in the previous 6 months with at least 1 seizure in the previous 3 months.
  4. Age: ≥16 years (at the time of obtaining consent)
  5. Outpatients
  6. Subjects are able to write a seizure diary.
  7. Subjects understand and sign written . If a subject is under 20 years at the time of obtaining consent, a subject and a legally acceptable representative (e.g., a parent or a custodian) sign written consent to participate in this study.
  8. Gender: Male or female If female, and of , be using an acceptable form of .
  9. \<450 millisecond (msec) or \<480msec for subjects with Bundle Branch Block - values based on either single values or triplicate ECG averaged QTc values obtained over a brief recording period.
  10. Subjects are able to comply with dosing of products and all study procedures.

Exclusion criteria

Exclusion Criteria:

  1. Subjects having seizure types other than partial seizure or generalized tonic clonic seizures with or without myoclonus. Subjects having status epilepticus within the 6 months prior to the start of study treatment.
  2. Subjects with a history of treatment with AEDs (≥2 weeks) during 6 months before the start of treatment with the product.
  3. Subjects with a history of treatment with lamotrigine.
  4. Subjects with a history of rash associated with other AED treatment.
  5. Subjects with a history of substance (including alcohol and drugs) dependence within 12 months before the start of investigational product or abuse within 1 month before the start of investigational product according to .
  6. Subjects with an acute or chronic illness likely to impair drug absorption, distribution, metabolism or excretion or with any unstable physical symptoms likely to require hospitalization during participation in the study.
  7. Subjects with a severe psychiatric disorder which affects the procedure of study or drug assessment.
  8. Subjects with an acute or progressive neurological disorder or an organic disease.
  9. Subjects with any chronic cardiac, renal, or hepatic medical condition. Any patient with these conditions are excluded from the study even if these conditions are being controlled with chronic therapy.
  10. Subjects with an unstable liver disease (as defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminaemia, oesophageal or gastric varices or persistent jaundice), cirrhosis, known biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
  11. Female subjects who are pregnant or lactating, who may be pregnant, or who plan for pregnancy during the study.
  12. Subjects taking inducers of lamotrigine glucuronidation (i.e., rifampicin, lopinavir/ritonavir), atazanavir/ritonavir, risperidone, oral or hormone drug which includes estrogen.
  13. Subjects having participated in other clinical study within 3 months before the start of investigational product.
  14. Subjects who have active suicidal plan/intent or have had active suicidal thoughts in the past 3 months before the start of investigational product or who have history of suicide attempt in the last 1 year before the start of investigational product or more than 1 lifetime suicide attempt.
  15. Subjects whom the investigator or subinvestigator considers ineligible for the study.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
70 participants (actual)

Study arms

  • Experimental
    Lamotrigine

    No comparison.

    Drug: Lamictal

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Were Seizure Free in the Maintenance Phase (Across Seizure Types and by Seizure Type Within 6 Months Prior to the Start of the Study)

    Participants were considered to be seizure free if they did not report any seizures during the Maintenance Phase. Seizure types are defined as: ALL=any type of seizure; A: simple partial seizures, B: complex partial seizures; C: partial seizures evolving to secondary generation seizures; D5: tonic-clonic seizures. Simple partial seizures are seizures that affect only a small region of the brain, often the temporal lobes or hippocampi. Complex partial seizures are epileptic seizures that are associated with bilateral cerebral hemisphere involvement and cause impairment of awareness or responsiveness. Partial seizures evolving to secondary generation seizures are seizures that start as partial seizures, then spread to include the entire brain. Tonic-clonic seizures are a type of generalized seizure that affects the entire brain.

    Time frame: Weeks 7 to 30

Secondary outcomes

  1. Time to Withdrawal/Dropout From the Study (Across Seizure Types and by Seizure Type in Past 6 Months in the Escalation and Maintenance Phases)

    Time to withdrawal is defined as the time from the start of treatment until withdrawal from the study. Seizure types are defined as: ALL=any type of seizure; A: simple partial seizures, B: complex partial seizures; C: partial seizures evolving to secondary generation seizures; D5: tonic-clonic seizures. Simple partial seizures are seizures which affect only a small region of the brain, often the temporal lobes or hippocampi. Simple partial seizures are seizures that affect only a small region of the brain, often the temporal lobes or hippocampi. Complex partial seizures are epileptic seizures that are associated with bilateral cerebral hemisphere involvement and cause impairment of awareness or responsiveness. Partial seizures evolving to secondary generation seizures are seizures that start as partial seizures, then spread to include the entire brain. Tonic-clonic seizures are a type of generalized seizure that affects the entire brain.

    Time frame: up to Week 30

  2. Time to the First Seizure in the Maintenance Phase (Across Seizure Types and by Seizure Type)

    The time to the first seizure in the Maintenance Phase is measured at the time the first seizure occurred in the Maintenance Phase. Seizure types are defined as: ALL=any type of seizure; A: simple partial seizures, B: complex partial seizures; C: partial seizures evolving to secondary generation seizures; D5: tonic-clonic seizures. Simple partial seizures are seizures that affect only a small region of the brain, often the temporal lobes or hippocampi. Complex partial seizures are epileptic seizures that are associated with bilateral cerebral hemisphere involvement and cause impairment of awareness or responsiveness. Partial seizures evolving to secondary generation seizures are seizures that start as partial seizures, then spread to include the entire brain. Tonic-clonic seizures are a type of generalized seizure that affects the entire brain.

    Time frame: Weeks 7 to 30

07

Results

Posted Dec 3, 2013

Participant flow

A total of 70 participants were enrolled; 3 participants were screened but withdrew from the study before prescription of the first investigational product (67), and only 65 of the participants received at least one dose of the investigational product which comprised the safety population.

Participant flow — Overall Study
MilestoneLamotrigine
Started67
Begin escalation phase (ep; 6 weeks)67
Received treatment65
Complete ep (6 weeks)52
Begin maintenance phase (mp; 24 weeks)52
Complete mp (24 weeks)42
Begin extension phase (exp; gt= 24weeks)19
Complete exp (gt= 24 weeks)19
Completed32
Not completed35
Withdrew: Adverse event18
Withdrew: Lack of efficacy7
Withdrew: Protocol violation1
Withdrew: Protocol-defined stopping criteria2
Withdrew: Physician decision4
Withdrew: Withdrawal by subject3

Outcome measures

PrimaryNumber of Participants Who Were Seizure Free in the Maintenance Phase (Across Seizure Types and by Seizure Type Within 6 Months Prior to the Start of the Study)

Participants were considered to be seizure free if they did not report any seizures during the Maintenance Phase. Seizure types are defined as: ALL=any type of seizure; A: simple partial seizures, B: complex partial seizures; C: partial seizures evolving to secondary generation seizures; D5: tonic-clonic seizures. Simple partial seizures are seizures that affect only a small region of the brain, often the temporal lobes or hippocampi. Complex partial seizures are epileptic seizures that are associated with bilateral cerebral hemisphere involvement and cause impairment of awareness or responsiveness. Partial seizures evolving to secondary generation seizures are seizures that start as partial seizures, then spread to include the entire brain. Tonic-clonic seizures are a type of generalized seizure that affects the entire brain.

Time frame:
Weeks 7 to 30
Reported as:
Number · participants
Number of Participants Who Were Seizure Free in the Maintenance Phase (Across Seizure Types and by Seizure Type Within 6 Months Prior to the Start of the Study)
participantsLamotrigine
All, n=6528
A+B+C, n=5522
A+B, n=4217
C, n=3323
D5, n=108
Statistical analysis
  • Lamotrigine · Percentage of participants: 43.1 · 95% CI 30.85 to 55.96The estimated value reflects the percentage of participants who were seizure free for all seizures.
  • Lamotrigine · Percentage of participants: 40.0 · 95% CI 27.02 to 54.09The estimated value reflects the percentage of participants who were seizure free for A+B+C seizures.
  • Lamotrigine · Percentage of participants: 40.5 · 95% CI 25.63 to 56.72The estimated value reflects the percentage of participants who were seizure free for A+B seizures.
  • Lamotrigine · Percentage of participants: 69.7 · 95% CI 51.29 to 84.41The estimated value reflects the percentage of participants who were seizure free for C seizures.
  • Lamotrigine · Percentage of participants: 80.0 · 95% CI 44.39 to 97.48The estimated value reflects the percentage of participants who were seizure free for D5 seizures.
SecondaryTime to Withdrawal/Dropout From the Study (Across Seizure Types and by Seizure Type in Past 6 Months in the Escalation and Maintenance Phases)

Time to withdrawal is defined as the time from the start of treatment until withdrawal from the study. Seizure types are defined as: ALL=any type of seizure; A: simple partial seizures, B: complex partial seizures; C: partial seizures evolving to secondary generation seizures; D5: tonic-clonic seizures. Simple partial seizures are seizures which affect only a small region of the brain, often the temporal lobes or hippocampi. Simple partial seizures are seizures that affect only a small region of the brain, often the temporal lobes or hippocampi. Complex partial seizures are epileptic seizures that are associated with bilateral cerebral hemisphere involvement and cause impairment of awareness or responsiveness. Partial seizures evolving to secondary generation seizures are seizures that start as partial seizures, then spread to include the entire brain. Tonic-clonic seizures are a type of generalized seizure that affects the entire brain.

Time frame:
up to Week 30
Reported as:
Mean · Days
Time to Withdrawal/Dropout From the Study (Across Seizure Types and by Seizure Type in Past 6 Months in the Escalation and Maintenance Phases)
DaysLamotrigine
All, n=65150.0 ± 8.99
A+B+C, n=55148.4 ± 9.72
A+B, n=42147.9 ± 10.72
C, n=33168.0 ± 10.91
D5, n=1014.6 ± 0.54
SecondaryTime to the First Seizure in the Maintenance Phase (Across Seizure Types and by Seizure Type)

The time to the first seizure in the Maintenance Phase is measured at the time the first seizure occurred in the Maintenance Phase. Seizure types are defined as: ALL=any type of seizure; A: simple partial seizures, B: complex partial seizures; C: partial seizures evolving to secondary generation seizures; D5: tonic-clonic seizures. Simple partial seizures are seizures that affect only a small region of the brain, often the temporal lobes or hippocampi. Complex partial seizures are epileptic seizures that are associated with bilateral cerebral hemisphere involvement and cause impairment of awareness or responsiveness. Partial seizures evolving to secondary generation seizures are seizures that start as partial seizures, then spread to include the entire brain. Tonic-clonic seizures are a type of generalized seizure that affects the entire brain.

Time frame:
Weeks 7 to 30
Reported as:
Mean · Days
Time to the First Seizure in the Maintenance Phase (Across Seizure Types and by Seizure Type)
DaysLamotrigine
All, n=52103.0 ± 9.43
A+B+C, n=44100.4 ± 10.44
A+B, n=3494.2 ± 12.22
C, n=29113.3 ± 12.06
D5, n=8NA ± NA

Adverse events

Collected over Serious adverse events (SAEs) and non-serious AEs were collected from study medication start until the end of treatment (up to Week 54).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lamotrigine—8/65 (12.3%)38/65 (58.5%)
Most frequent serious events
Most frequent serious events
EventLamotrigine
EpilepsyNervous system disorders2/65
HaemorrhoidsGastrointestinal disorders1/65
Gastrooesophageal reflux diseaseGastrointestinal disorders1/65
Intestinal obstructionGastrointestinal disorders1/65
Sick sinus syndromeCardiac disorders1/65
Electrocardiogram QT prolongedInvestigations1/65
Decreased appetiteMetabolism and nutrition disorders1/65
Stevens-Johnson syndromeSkin and subcutaneous tissue disorders1/65
Pulmonary contusionInjury, poisoning and procedural complications1/65
Post procedural haemorrhageInjury, poisoning and procedural complications1/65
Most frequent other events
Most frequent other events
EventLamotrigine
NasopharyngitisInfections and infestations15/65
HeadacheNervous system disorders14/65
RashSkin and subcutaneous tissue disorders8/65
NauseaGastrointestinal disorders6/65
DizzinessNervous system disorders4/65
Drug eruptionSkin and subcutaneous tissue disorders4/65
Abdominal pain upperGastrointestinal disorders4/65
InsomniaPsychiatric disorders4/65

Baseline characteristics

Baseline data were collected in members of the Safety Population, comprised of all participants who had taken at least one dose of investigational product.

Age, Continuous
Age, Continuous(Years)Lamotrigine
Mean37.3 ± 20.20
Sex: Female, Male
Sex: Female, Male(Participants)Lamotrigine
Female26
Male39
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Lamotrigine
Asian - East Asian Heritage26
Asian - Japanese Heritage39
08

Study locations

13 sites
  • GSK Investigational Site
    Fukuoka, 807-8555, Japan
  • GSK Investigational Site
    Ibaraki, 317-0077, Japan
  • GSK Investigational Site
    Kagoshima, 892-0844, Japan
  • GSK Investigational Site
    Kyoto, 611-0042, Japan
  • GSK Investigational Site
    Miyagi, 980-8574, Japan
  • GSK Investigational Site
    Nara, 634-8522, Japan
  • GSK Investigational Site
    Niigata, 950-1197, Japan
  • GSK Investigational Site
    Niigata, 950-2085, Japan
  • GSK Investigational Site
    Okayama, 703-8265, Japan
  • GSK Investigational Site
    Osaka, 560-8565, Japan
  • GSK Investigational Site
    Shizuoka, 430-8558, Japan
  • GSK Investigational Site
    Seoul, 110-744, Korea, Republic of
  • GSK Investigational Site
    Seoul, 135-710, Korea, Republic of
09

References and documents

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2011, a primary completion of Mar 2013 and a completion of Oct 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2013, 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 1, 2011
First posted
Sep 12, 2011
Start
Sep 2011
Primary completionActual
Mar 2013
CompletionActual
Oct 2014
Results first posted
Dec 3, 2013
Last update
Oct 20, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 20, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01431963
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Sep 12, 2011
Start date
Sep 2011
Primary completion
Mar 2013
Completion
Oct 2014
Results posted
Dec 3, 2013
Last update
Oct 20, 2016

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lamotrigine

Start the discussion